S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people
Reuters
Published Jun 30, 2022 03:24AM ET
SEOUL (Reuters) - South Korea on Thursday authorised AstraZeneca (NASDAQ:AZN) PLC's antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease the pandemic burden on the healthcare system.
The Ministry of Food and Drug Safety granted emergency use authorisation for 20,000 doses of Evusheld for individuals aged 12 years and older who have not been exposed to the coronavirus.
Nearly 87% of South Korea's 52 million people are fully vaccinated against COVID-19, while 65% have also had a booster, government data showed. However, individuals with compromised immune systems or those with a history of severe adverse reaction to vaccines may need alternative prevention options.
Evusheld could be used for people whose immune systems are unlikely to mount adequate responses to COVID-19 vaccination or for whom vaccination is not recommended, the ministry said.
AstraZeneca in March said Evusheld retained its neutralising activity against the Omicron coronavirus variant in an independent study, and that it reduced the risk of symptomatic COVID-19 by 77% in trials.
While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, Evusheld contains laboratory-made antibodies designed to linger in the body for months to contain the virus in case of infection.
The British drugmaker's therapy has already been authorised in the United States and its use has been recommended by the European Medicines Agency.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.